Home > Back to Publisher > Report Information

China Pharmaceutical Regulatory Report 2011

Pacific Bridge Medical
January 1, 2011
74 Pages - SKU: PACB6382873

Abstract Table of Contents Related Reports

Countries covered: China

This regulatory report includes an overview of the pharmaceutical and healthcare industry in China, as well as a discussion of all the relevant Chinese laws and regulations that govern the testing, registration, manufacture, import, marketing, and sale of pharmaceutical products. Specific topics for drug companies include product registration, pricing and reimbursement, importation, GMP, GCP, orphan drugs, and intellectual property protection.

This report's appendix contains a full translation of the revised Administrative Provisions for Drug Registration, the recent overhaul of China's drug regulations. It also contains the annexes to this document detailing dossier submission requirements. These will help drug companies in their product registration process in China.

Updates for 2011 include:

Latest healthcare developments in China and their impact on foreign drug companies
China’s new healthcare reform policies and its impact on pharmaceutical regulations
New Chinese pharmaceutical regulations and updated policies on drug manufacturing (GMP), distribution and clinical research in China
An expanded and revised list of Clinical Research Organizations in China for outsourcing by foreign drug companies (Appendix)

I. China Pharmaceutical Industry Overview: A. Overview; B. China Pharmaceutical Market Trends; C. China’s Pharmaceutical Distribution System; D. Brief Overview of China's Pharmaceutical Regulations; E. The State Food and Drug Administration
II. The China Healthcare System: A. History of China’s Healthcare System; B. Struggling Healthcare Services Sector; C. 2009 Healthcare Reform; C. Hospitals and Medical Resources; D. Health Insurance in China
III. Drug Registration Regulations: A. Drug Registration Policy; B. Classification of Drugs; C. Drug Registration Application; D. Application Documents for New Drug Registration; E. Technical Review Guidance for Registration Documents; F. New Drug Registration Process; G. OTC New Drug Registration Process; H. Drug Registration Re-examination; I. Drug Registration Statistics; J. Classification of Combination Drug-Device Products; K. New Regulatory Changes
IV. Drug Pricing Regulations: A. Overview of Drug Pricing; B. Controls on Drug Pricing; C. National Reimbursement Drug List; V. Pharmaceutical Research and Development and Related Regulations; A. China's Research and Development Climate; B. Clinical Research; C. Good Clinical Practice (GCP); D. GCP-Certified Clinical Research Centers; E. Good Laboratory Practice (GLP); F. Adverse Event Reporting Requirements
VI. Pharmaceutical Manufacturing Regulations: A. Overview of Manufacturing in China; B. GMP Regulations; C. GMP Certification; D. Drug Manufacturing Administration; E. Drug Manufacturing Certificate; F. Biological Products
VII. Selling Pharmaceuticals and Related Regulations: A. WTO Agreement on Drug Sales; B. Drug Sales to Hospitals; C. Drug Purchasing System; D. Selling Drugs in Drug Stores; E. Internet Drug Sales; F. Distribution Regulations; G. OTC Drug Sales; H. Regulations on Importing Drugs; I. Drug Recalls; J. Drug Safety; K. Authorized Quality Person
VIII. Marketing Drugs in China and Related Regulations: A. Packaging Requirements
IX. Drug Advertising Regulations
X. Intellectual Property Protection and Patents: A. Intellectual Property in the China Pharmaceutical Market; B. Pharmaceutical Companies Experiencing IPR Problems; C. Administrative Protection (AP)
XI. Conclusion
APPENDICES:: Application Form for Drug Registration; Listing of CROs in China; Regulatory Specifics for Clinical Trials in China; Administrative Provisions for Drug Registration (translated law); Registration for TCM (translated law); Registration for Chemical Drugs (translated law); Registration for Biological Drugs (translated law); Supplemental Drug Application Registration (translated law); Drug Re-registration Application (translated law); Drug Monitoring Periods; Application and Approval Procedures and Timeline for Imported Drugs; Application and Approval Procedures and Timeline for Clinical Trials; Listing of SFDA-affiliated organizations in China; Healthcare statistics and pharmaceutical markets in Asia (charts)

More China Regulation & Policy Reports

China’s Guidebook for Pharmaceutical Patent Protection by Access China Management Consulting Ltd.
China’s Guidebook for Pharmaceutical Patent Protection is an essential resource for overseas and multinational pharmaceutical companies to achieve a successful patent protection for their intellectual ...

China Chinese Patent Drug Processing Industry, 2012 by Reports From China
China chinese patent drug processing industry, 2012 is valuable for anyone who wants to invest in the chinese patent drug processing industry, to get Chinese ...

China Drug Patent Inventor Report - 2011 Publication List by DrugPatentWatch
TheChina Drug Patent Inventor Reportprofiles China-based inventors leading pharmaceutical innovation. Using data on drugs approved from 2000 to 2010, this report provides complete lists of: Top ...

China Pharmaceutical Equipment Industry Report, 2011-2012 by Research in China
In recent years, Chinese pharmaceutical equipment industry has witnessed significant growth in both product quality and technological content, as well as steady rise of sales ...

Healthcare Reform in China by Business Insights
China's pharmaceutical market is growing rapidly in step with it's wider economy. The government aims to extend healthcare coverage to it's 1.3bn citizens, which will ...

See all reports like this >>

More China Reports

D&B Country RiskLine Report: China by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

Country Report China February 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

Country Report China January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

D&B Country Report: China by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...

Wine - BRIC (Brazil, Russia, India, China) Industry Guide by MarketLine
Datamonitor's Wine - BRIC (Brazil, Russia, India, China) Industry Guide is an essential resource for top-level data and analysis covering the BRIC (Brazil, Russia, India, ...

See all reports like this >>

China Pharmaceutical Regulatory Report 2011

Share this report

Other tasks

Research Assistance

Related Markets

Regulation & Policy Reports

Free Alert Me service